Investment Thesis
LENZ is a pre-profitability biotech company with severe operating losses ($44.1M) and deteriorating net income (-65% YoY) despite minimal revenue ($1.9M). With a cash burn rate of $33.6M annually against only $24.8M in cash, the company faces critical liquidity challenges within the next 9-12 months unless capital is raised. While the strong balance sheet ($246.5M equity, zero debt) provides some cushion, the company must demonstrate rapid revenue acceleration and expense management to avoid shareholder dilution through future funding rounds.
Strengths
- Strong balance sheet with $246.5M stockholders equity and zero long-term debt
- Excellent liquidity position with 10.40x current ratio providing short-term financial flexibility
- Early revenue generation of $1.9M indicates commercialization has begun
Risks
- Severe cash burn rate of $33.6M annually against only $24.8M cash on hand creates less than 1-year runway
- Operating losses of $44.1M with net income deteriorating 65% YoY signal worsening financial trajectory
- Massive negative operating margin (-2321.7%) and minimal revenue indicate operations are not sustainable without continuous capital infusion
Key Metrics to Watch
- Quarterly revenue growth rate and path to profitability
- Monthly cash burn rate and updated cash runway estimate
- Operating expense trends, particularly R&D spending efficiency
- Regulatory approvals and clinical trial progress for product pipeline
- Additional capital raises and dilution impact on existing shareholders
Financial Metrics
Revenue
1.9M
Net Income
-41.5M
EPS (Diluted)
$-1.32
Free Cash Flow
-33.6M
Total Assets
272.5M
Cash
24.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,321.7%
Net Margin
-2,182.4%
ROE
-16.8%
ROA
-15.2%
FCF Margin
-1,767.5%
Balance Sheet & Liquidity
Current Ratio
10.40x
Quick Ratio
10.26x
Debt/Equity
0.00x
Debt/Assets
9.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-12T07:40:49.354568 |
Data as of: 2026-03-31 |
Powered by Claude AI